Literature DB >> 1905394

A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children.

E Isolauri1, M Juntunen, T Rautanen, P Sillanaukee, T Koivula.   

Abstract

To determine the effect of a human Lactobacillus strain (Lactobacillus casei sp strain GG, Gefilac) on recovery from acute diarrhea (82% rotavirus), 71 well-nourished children between 4 and 45 months of age were studied. After oral rehydration, the patients randomly received either Lactobacillus GG-fermented milk product, 125 g (10(10-11) colony-forming units) twice daily (group 1); Lactobacillus GG freeze-dried powder, one dose (10(10-11) colony-forming units) twice daily (group 2); or a placebo, a pasteurized yogurt (group 3) 125 g twice daily; each diet was given for 5 days, in addition to normal full diet otherwise free of fermented dairy products. The mean (SD) duration of diarrhea after commencing the therapy was significantly shorter in group 1 (1.4 [0.8] days) and in group 2 (1.4 [0.8] days) than in group 3 (2.4 [1.1] days); F = 8.70, P less than 0.001. After rehydration, each dietary group maintained a positive weight trend. The urinary lactulose-mannitol recovery ratios (means [95% confidence intervals]) on admission were 0.09 (0.03, 0.24) in group 1, 0.12 (0.07, 0.22) in group 2, and 0.08 (0.04, 0.18) in group 3; no significant alterations in intestinal permeability were observed at retesting after 2 days of realimentation. The result indicates that early nutritional repletion after rehydration causes no mucosal disruption and is beneficial for recovery from diarrhea. It is further suggested that Lactobacillus GG in the form of fermented milk or freeze-dried powder is effective in shortening the course of acute diarrhea.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1905394

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  103 in total

Review 1.  The scientific basis for probiotic strains of Lactobacillus.

Authors:  G Reid
Journal:  Appl Environ Microbiol       Date:  1999-09       Impact factor: 4.792

Review 2.  Probiotics: a role in the treatment of intestinal infection and inflammation?

Authors:  E Isolauri; P V Kirjavainen; S Salminen
Journal:  Gut       Date:  2002-05       Impact factor: 23.059

Review 3.  Probiotics and immune response.

Authors:  Stephanie Blum; Dirk Haller; Andrea Pfeifer; Eduardo J Schiffrin
Journal:  Clin Rev Allergy Immunol       Date:  2002-06       Impact factor: 8.667

Review 4.  The influence of yogurt/Lactobacillus on the innate and acquired immune response.

Authors:  Andrea T Borchers; Carl L Keen; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2002-06       Impact factor: 8.667

5.  Bacteriological evaluation of dog and cat diets that claim to contain probiotics.

Authors:  J Scott Weese; Luis Arroyo
Journal:  Can Vet J       Date:  2003-03       Impact factor: 1.008

Review 6.  Pro and anti: the biotics of allergic disease.

Authors:  J Crane
Journal:  Thorax       Date:  2002-10       Impact factor: 9.139

7.  Probiotic Formulations: Application and Status as Pharmaceuticals-A Review.

Authors:  V Sreeja; Jashbhai B Prajapati
Journal:  Probiotics Antimicrob Proteins       Date:  2013-06       Impact factor: 4.609

8.  Probiotics and Gastrointestinal Disease: Clinical Evidence and Basic Science.

Authors:  Elaine O Petrof
Journal:  Antiinflamm Antiallergy Agents Med Chem       Date:  2009-09-01

9.  Signalling mechanisms involved in the induction of inducible nitric oxide synthase by Lactobacillus rhamnosus GG, endotoxin, and lipoteichoic acid.

Authors:  Riku Korhonen; Riitta Korpela; Eeva Moilanen
Journal:  Inflammation       Date:  2002-10       Impact factor: 4.092

10.  Lactobacillus rhamnosus GG on rotavirus-induced injury of ileal epithelium in gnotobiotic pigs.

Authors:  Fangning Liu; Guohua Li; Ke Wen; Shaoping Wu; Yongguo Zhang; Tammy Bui; Xingdong Yang; Jacob Kocher; Jun Sun; Bernard Jortner; Lijuan Yuan
Journal:  J Pediatr Gastroenterol Nutr       Date:  2013-12       Impact factor: 2.839

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.